A Novel Agent for a Rare Bone Marrow Disease


The FDA has approved ruxolitinib (Jakafi, Incyte) for myelofibrosis, a rare bone marrow disease. The agent inhibits the JAK1 and JAK2 enzymes, which play a role in blood regulation and immunological functioning.


Readings & Resources (click to view)

Source: FDA.

For more on the approval, visit

Submit a Comment

Your email address will not be published. Required fields are marked *

2 × five =